Altimmune, Inc. (3G0.F)
| Previous Close | 6.00 |
| Open | 5.75 |
| Bid | 5.50 x 440000 |
| Ask | 5.55 x 420000 |
| Day's Range | 5.45 - 5.75 |
| 52 Week Range | 1.97 - 13.70 |
| Volume | |
| Avg. Volume | 313 |
| Market Cap | 386.488M |
| Beta (5Y Monthly) | 0.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.49 |
| Earnings Date | Aug 08, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Jan 20, 2017 |
| 1y Target Est | 30.86 |
GlobeNewswireAltimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Follow-on analyses of non-invasive tests from Phase 1 trials in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) suggest the potential for meaningful histologic improvements with MASH biopsy readouts in Q1 2025 Based on a quantitative systems pharmacology (QSP) computational model, pemvidutide’s GLP-1/glucagon dual agonism could have additive effects on MASH resolution and fibrosis improvement compared with GLP-1 alone Lipidomic profiling reinforces the disease modifying potentia
- Baystreet
Invest in the GLP-1 Drug Market With This New ETF
The market for anti-obesity drugs is massive one, worth potentially $100 billion or more based on some ...
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 29, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Jefferies Global Healthcare Conference (New York, NY)Wednesday, June 5, 2024Fireside Chat at 2:00 p.m. Eastern TimeGoldman Sachs Global Healthcare Conference (Miami Beach, FL)Wednesday, June 12, 2024Fireside Chat at 9:20
